Product Name :
ZL0580
Description:
ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 domain of BRD4. ZL0580 induces HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter.
CAS:
2377151-10-3
Molecular Weight:
532.53
Formula:
C25H23F3N4O4S
Chemical Name:
(2S)-N-phenyl-1-[4-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)benzenesulfonyl]pyrrolidine-2-carboxamide
Smiles :
O=C(NC1C=CC(=CC=1)C(F)(F)F)NC1C=CC(=CC=1)S(=O)(=O)N1CCC[C@H]1C(=O)NC1C=CC=CC=1
InChiKey:
DKFYGSWCJGXEJY-QFIPXVFZSA-N
InChi :
InChI=1S/C25H23F3N4O4S/c26-25(27,28)17-8-10-19(11-9-17)30-24(34)31-20-12-14-21(15-13-20)37(35,36)32-16-4-7-22(32)23(33)29-18-5-2-1-3-6-18/h1-3,5-6,8-15,22H,4,7,16H2,(H,29,33)(H2,30,31,34)/t22-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 domain of BRD4. ZL0580 induces HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter.|Product information|CAS Number: 2377151-10-3|Molecular Weight: 532.53|Formula: C25H23F3N4O4S|Chemical Name: (2S)-N-phenyl-1-[4-({[4-(trifluoromethyl)phenyl]carbamoyl}amino)benzenesulfonyl]pyrrolidine-2-carboxamide|Smiles: O=C(NC1C=CC(=CC=1)C(F)(F)F)NC1C=CC(=CC=1)S(=O)(=O)N1CCC[C@H]1C(=O)NC1C=CC=CC=1|InChiKey: DKFYGSWCJGXEJY-QFIPXVFZSA-N|InChi: InChI=1S/C25H23F3N4O4S/c26-25(27,28)17-8-10-19(11-9-17)30-24(34)31-20-12-14-21(15-13-20)37(35,36)32-16-4-7-22(32)23(33)29-18-5-2-1-3-6-18/h1-3,5-6,8-15,22H,4,7,16H2,(H,29,33)(H2,30,31,34)/t22-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (469.{{Bamlanivimab} MedChemExpress|{Bamlanivimab} Anti-infection|{Bamlanivimab} Protocol|{Bamlanivimab} Formula|{Bamlanivimab} custom synthesis|{Bamlanivimab} Epigenetic Reader Domain} 46 mM; Need ultrasonic).{{Bergamottin} medchemexpress|{Bergamottin} Cytochrome P450|{Bergamottin} Purity & Documentation|{Bergamottin} In Vitro|{Bergamottin} supplier|{Bergamottin} Autophagy} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:35670838 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|ZL0580 (8 μM, 2 days, PBMCs of viremic HIV-infected individuals) induces HIV transcriptional suppression with low toxicity. ZL0580 treatment (10 μM) suppresses both PMA-stimulated and basal HIV transcription.|Products are for research use only. Not for human use.|